Literature DB >> 18350285

A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance.

Michele Basso, Alessandra Cassano, Anna Modoni, Daniele Spada, Nunziatina Trigila, Michela Quirino, Giovanni Schinzari, Carlo Barone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18350285     DOI： 10.1007/s00228-008-0474-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

Authors:  F Grolleau; L Gamelin; M Boisdron-Celle; B Lapied; M Pelhate; E Gamelin
Journal:  J Neurophysiol       Date:  2001-05       Impact factor: 2.714

2.  Potassium current suppression in patients with peripheral nerve hyperexcitability.

Authors:  T Nagado; K Arimura; Y Sonoda; A Kurono; Y Horikiri; A Kameyama; M Kameyama; O Pongs; M Osame
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

3.  Acute oxaliplatin-induced peripheral nerve hyperexcitability.

Authors:  Richard H Wilson; Tanya Lehky; Rebecca R Thomas; Mary G Quinn; Mary Kay Floeter; Jean L Grem
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

Review 4.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

5.  Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia.

Authors:  I K Hart; C Waters; A Vincent; C Newland; D Beeson; O Pongs; C Morris; J Newsom-Davis
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

Review 6.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Authors:  C R Culy; D Clemett; L R Wiseman
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

7.  Interactions of N-terminal and C-terminal parts of the small conductance Ca2+ activated K+ channel, hSK3.

Authors:  Eva Frei; Isabell Spindler; Stephan Grissmer; Heike Jäger
Journal:  Cell Physiol Biochem       Date:  2006

8.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Authors:  Richard G Webster; Keith L Brain; Richard H Wilson; Jean L Grem; Angela Vincent
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

9.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

Review 10.  Oxaliplatin-safety profile: neurotoxicity.

Authors:  Axel Grothey
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929
View more
  4 in total

1.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

2.  Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report.

Authors:  Min-Han Tan; Wen Yee Chay; Jia Hui Ng; Bin Tean Teh; Lita Chew
Journal:  J Med Case Rep       Date:  2010-02-02

3.  Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy.

Authors:  Manisha Chandar; Robert de Wilton Marsh
Journal:  Case Rep Oncol       Date:  2015-03-04

Review 4.  Pancreatic cancer and FOLFIRINOX: a new era and new questions.

Authors:  Robert De W Marsh; Mark S Talamonti; Matthew Harold Katz; Joseph M Herman
Journal:  Cancer Med       Date:  2015-02-19       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.